Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
RMD Open|August 13, 2021
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3Daniel Aletaha, René Westhovens, Cecile Gaujoux-Viala, et al.
Annals of the Rheumatic Diseases|November 6, 2021
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 yearsKevin L Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, et al.
JAMA|July 24, 2019
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical TrialMark C Genovese, Kenneth Kalunian, Jacques-Eric Gottenberg, et al.
Annals of the Rheumatic Diseases|November 8, 2014
TGFβ responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasivenessStephanie M Stanford, German R Aleman Muench, Beatrix Bartok, et al.
Pain|March 18, 2014
Differential distribution of PI3K isoforms in spinal cord and dorsal root ganglia: potential roles in acute inflammatory painMathias Leinders, Fred J Koehrn, Beatrix Bartok, et al.
Rheumatology and Therapy|October 9, 2022
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
Modern Rheumatology|August 3, 2022
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3)Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Modern Rheumatology|April 2, 2022
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 yearsNaoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Modern Rheumatology|December 15, 2021
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Modern Rheumatology|December 4, 2020
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2)Tsutomu Takeuchi, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Pageof 3